ES2655492T3 - Formulaciones que comprenden cloruro de metiltioninio - Google Patents
Formulaciones que comprenden cloruro de metiltioninio Download PDFInfo
- Publication number
- ES2655492T3 ES2655492T3 ES11802119.5T ES11802119T ES2655492T3 ES 2655492 T3 ES2655492 T3 ES 2655492T3 ES 11802119 T ES11802119 T ES 11802119T ES 2655492 T3 ES2655492 T3 ES 2655492T3
- Authority
- ES
- Spain
- Prior art keywords
- mtc
- tablets
- tablet
- dissolution
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41816410P | 2010-11-30 | 2010-11-30 | |
| US418164P | 2010-11-30 | ||
| PCT/GB2011/001662 WO2012072977A2 (en) | 2010-11-30 | 2011-11-30 | Compound formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2655492T3 true ES2655492T3 (es) | 2018-02-20 |
Family
ID=45418703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11802119.5T Active ES2655492T3 (es) | 2010-11-30 | 2011-11-30 | Formulaciones que comprenden cloruro de metiltioninio |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9192611B2 (https=) |
| EP (1) | EP2645994B1 (https=) |
| JP (1) | JP6093707B2 (https=) |
| CN (1) | CN103379901B (https=) |
| AU (1) | AU2011334679B2 (https=) |
| CA (1) | CA2818068C (https=) |
| ES (1) | ES2655492T3 (https=) |
| MY (1) | MY163074A (https=) |
| SG (2) | SG10201602111VA (https=) |
| WO (1) | WO2012072977A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014153444A (ja) * | 2013-02-06 | 2014-08-25 | Konica Minolta Inc | 位相差フィルム、偏光板及び液晶表示装置 |
| JP7073330B2 (ja) | 2016-07-25 | 2022-05-23 | ウィスタ ラボラトリーズ リミテッド | ジアミノフェノチアジンの投与及び投与量 |
| FR3104438B1 (fr) * | 2019-12-12 | 2021-11-19 | Univ Bordeaux | Formulation pour le bleu de methylene et procede |
| AU2023279800A1 (en) | 2022-05-31 | 2024-12-19 | TauRx Therapeutics Management Ltd | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
| EP4590306A1 (en) | 2022-09-21 | 2025-07-30 | Yin Sze Loh | Oral formulation of diaminophenothiazines and methods of making and using the same in the treatment and/or prevention of diseases |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880373A (en) | 1988-04-28 | 1989-11-14 | The Upjohn Company | Tablet press |
| JPH0840942A (ja) * | 1994-07-29 | 1996-02-13 | Kanegafuchi Chem Ind Co Ltd | 薬物放出制御製剤 |
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
| SI2322517T1 (sl) | 2004-09-23 | 2019-06-28 | Wista Laboratories Ltd. | Postopki za kemijsko sintezo in čiščenje diaminofenotiazinijevih spojin, vključno metiltioninijevega klorida (MTC) |
| CN101084204B (zh) * | 2004-09-23 | 2012-12-05 | 卫思道制药有限公司 | 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法 |
| ES2317313T3 (es) * | 2004-10-19 | 2009-04-16 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Composicion farmaceutica solida que comprende clorhidrato de donepezilo. |
| JP2009506053A (ja) * | 2005-08-24 | 2009-02-12 | ワイス | 酢酸バゼドキシフェン製剤 |
| US20070154545A1 (en) * | 2006-01-05 | 2007-07-05 | Julia Hrakovsky | Dry formulations of aripiprazole |
| ES2349322T7 (es) | 2006-03-29 | 2019-10-17 | Wista Lab Ltd | Sales de 3,7-diamino-10H-fenotiazina y su utilización |
| US20080317678A1 (en) * | 2007-06-22 | 2008-12-25 | Szymczak Christopher E | Laser Marked Dosage Forms |
| CA2701075C (en) | 2007-10-03 | 2019-02-12 | Wista Laboratories Ltd. | Therapeutic use of diaminophenothiazines. |
| EP2227766A2 (en) | 2007-11-05 | 2010-09-15 | Wista Laboratories Ltd. | Systems for clinical trials |
| JP5918136B2 (ja) * | 2009-09-24 | 2016-05-18 | ウィスタ ラボラトリーズ リミテッド | プロセス |
-
2011
- 2011-11-30 JP JP2013541414A patent/JP6093707B2/ja active Active
- 2011-11-30 MY MYPI2013001934A patent/MY163074A/en unknown
- 2011-11-30 AU AU2011334679A patent/AU2011334679B2/en active Active
- 2011-11-30 SG SG10201602111VA patent/SG10201602111VA/en unknown
- 2011-11-30 ES ES11802119.5T patent/ES2655492T3/es active Active
- 2011-11-30 SG SG2013040357A patent/SG190406A1/en unknown
- 2011-11-30 WO PCT/GB2011/001662 patent/WO2012072977A2/en not_active Ceased
- 2011-11-30 EP EP11802119.5A patent/EP2645994B1/en active Active
- 2011-11-30 CA CA2818068A patent/CA2818068C/en active Active
- 2011-11-30 CN CN201180057700.9A patent/CN103379901B/zh active Active
- 2011-11-30 US US13/989,953 patent/US9192611B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MY163074A (en) | 2017-08-15 |
| CA2818068C (en) | 2019-06-11 |
| WO2012072977A3 (en) | 2012-08-16 |
| JP6093707B2 (ja) | 2017-03-08 |
| EP2645994A2 (en) | 2013-10-09 |
| AU2011334679B2 (en) | 2016-12-15 |
| SG190406A1 (en) | 2013-06-28 |
| WO2012072977A8 (en) | 2012-09-20 |
| CN103379901A (zh) | 2013-10-30 |
| JP2013544272A (ja) | 2013-12-12 |
| CA2818068A1 (en) | 2012-06-07 |
| SG10201602111VA (en) | 2016-04-28 |
| CN103379901B (zh) | 2018-04-03 |
| US9192611B2 (en) | 2015-11-24 |
| US20130243858A1 (en) | 2013-09-19 |
| WO2012072977A2 (en) | 2012-06-07 |
| EP2645994B1 (en) | 2017-11-01 |
| AU2011334679A1 (en) | 2013-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102508739B1 (ko) | Magl 억제제의 결정형 | |
| EP2842549B1 (en) | Orally disintegrating tablet and method for producing same | |
| ES2655492T3 (es) | Formulaciones que comprenden cloruro de metiltioninio | |
| RU2690685C2 (ru) | Фармацевтические композиции, содержащие алпелисиб | |
| Abdelmonem et al. | Formulation and evaluation of baclofen-meloxicam orally disintegrating tablets (ODTs) using co-processed excipients and improvement of ODTs performance using six sigma method | |
| Alvarado et al. | In vitro biopharmaceutical equivalence of carbamazepine sodium tablets available in Lima, Peru | |
| Sutradhar et al. | Formulation and evaluation of taste masked oral dispersible tablets of domperidone using sublimation method | |
| ES2377552T3 (es) | Composiciones disueltas fácilmente y estables de candesartán cilexetilo preparadas con una granulación por vía húmeda | |
| Kumar et al. | Formulation and evaluation of piroxicam fast dissolving tablets using direct compression and sublimation method | |
| Kumar et al. | Development and characterization of melt-in-mouth tablets of haloperidol by sublimation technique | |
| ES2403193T3 (es) | Composiciones que comprenden alprazolam para el tratamiento del insomnio primario y del insomnio asociado con estados de ansiedad y procedimientos para su preparación | |
| Sharma et al. | A Review on Fast Dissolving Tablets | |
| Buwade et al. | Advantages of immediate release tablets over the other tablet forms | |
| Wanare et al. | Formulation and evaluation of fast dissolving tablets of azithromycin dihydrate using different super disintegrants | |
| Durge et al. | Formulation Development and Characterization of Anti-Retroviral Agents | |
| Rawat et al. | FORMULATION, DEVELOPMENTAND EVALUATION OF SUSTAINDED-RELEASE TABLET OF DOXOPHYLLINE | |
| ES2863402T3 (es) | Combinación de plantas oficinales y su uso en el tratamiento y/o prevención de trastornos del sueño | |
| Rana et al. | The formulation and evaluation of mouth dissolving tablet Levocetirizine by using synthetic Superdisintegrants | |
| Paškevičiūtė et al. | OF DICLOFENAC SODIUM CAPSULES | |
| Zin et al. | Preliminary Study on the Formulation of Syariah Compliant Generic Sustained Release Gliclazide Tablet Using Xanthan Gum | |
| Seshadri et al. | Formulation and characterization of mouth dissolving tablets containing benzodiazepine | |
| Dalvadi et al. | Formulation and evaluation of amisulpride orodispersible Tablet | |
| HK1184386A (en) | Formulations comprising methylthioninium chloride | |
| HK1184386B (en) | Formulations comprising methylthioninium chloride | |
| ES2422657B1 (es) | Composición farmacéutica sólida de cilostazol |